Showing 1387 results
-
Press release /LIBERTY is the first migraine prevention trial of its kind conducted specifically in patients who have tried multiple therapies without success, and are in need of additional treatment options…
-
Press release /Entresto (sacubitril/valsartan) reduced the composite of total (first and recurrent) heart failure hospitalizations and cardiovascular death although narrowly missed statistical significance (p = 0.…
-
Press release /Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global…
-
Ad hoc release /2025 target to increase patients reached in LMICs with strategic innovative medicines by 200% and the Novartis Flagship Programs by 50% - bringing potential reach to over 23 million patients across…
-
Press release /33 abstracts from the leading MS portfolio include data for Gilenya® (fingolimod), and investigational drugs siponimod (BAF312) and ofatumumab (OMB157) New research will be presented on…
-
Story /Jeff Weers’ passion inspired a new way of getting inhaled medicine past the body’s natural defenses to reach the lungs.
-
Press release /Cosentyx® (secukinumab) is the first new biologic treatment for hidradenitis suppurativa (HS) in nearly a decade, offering clinically meaningful results across the most debilitating symptoms1,2…
-
Ad hoc release /Novartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in terms of assets and geographies Key growth…
-
Press release /In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved the average hemoglobin (Hb) level versus baseline in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were…
-
Press release /Novartis has temporarily suspended production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at facilities in Ivrea, Italy and Millburn, New JerseyThis action has been taken out of an abundance of…